A new advancement in the treatment of metastatic triple-negative breast cancer

Metastatic triple-negative breast cancer (mTNBC) represents a major challenge for healthcare professionals. Characterized by high aggressiveness and resistance to conventional treatments, its prognosis is often less favorable than other types of breast cancer. This underscores the critical need for therapeutic innovations. Sacituzumab govitecan (SG), a newly approved antibody-drug conjugate, specifically targets TROP2, a protein overexpressed in mTNBC. This study aims to evaluate and analyze the efficacy and tolerability of this innovative treatment in patients who have already undergone multiple lines of therapy.